NCT04925609 2025-12-05
Briga-PED
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT01449461 2021-08-17
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Takeda
Phase 1/2 Completed
NCT03719898 2021-01-05
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT04260009 2020-03-05
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
Phase 1/2 Withdrawn